Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a net loss of $3.4 million, or $0.25 per share, for the fourth quarter, compared to a net loss of $12.7 million, or $1.19 per share, for the same period in 2024. For the full year 2025, Atara reported a net income of $32.7 million, or $2.61 per share, compared to a net loss of $85.4 million, or $11.41 per share, in 2024. The company’s cash, cash equivalents, and short-term investments totaled $8.5 million as of December 31, 2025, down from $42.5 million a year earlier. Atara's operational efficiencies have extended its cash runway through year-end 2026. The company has scheduled a Type A meeting with the FDA to discuss issues raised in a Complete Response Letter regarding its product tabelecleucel (tab-cel) for post-transplant lymphoproliferative disease (PTLD). Atara is committed to supporting its partner, Pierre Fabre Pharmaceuticals, in addressing these concerns. The company also amended its agreement with HealthCare Royalty, extending the due date for a $9 million cash payment to January 1, 2028, in exchange for a warrant to purchase 400,000 shares of common stock. Atara's focus remains on streamlining costs and supporting its partners in bringing innovative therapies to market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.